You are viewing the site in preview mode
Skip to main content
| |
Total (n = 220)
|
BRCA results known prior to surgery (n = 113)
|
BRCA results known after surgery (n = 107)
|
p-value
|
|---|
|
Age at diagnosis
|
|
Mean age (years)
|
47.3
|
45.7
|
49.1
|
<0.05
|
|
Range (years)
|
22.3 – 81.7
|
22.3 – 79.1
|
26.0 – 81.7
| |
|
Median age (years)
|
46.4
|
44.0
|
47.6
|
<0.05
|
|
Race
|
|
Caucasian
|
189 (85.9%)
|
97 (85.8%)
|
92 (86.0%)
|
NS
|
|
African American
|
14 (6.4%)
|
8 (7.1%)
|
6 (5.6%)
|
NS
|
|
Other
|
3 (1.4%)
|
2 (1.8%)
|
1 (0.9%)
|
NS
|
|
Unknown
|
14 (6.4%)
|
6 (5.3%)
|
8 (7.5%)
|
NS
|
|
Laterality
|
|
Unilateral
|
208 (94.5%)
|
106 (93.8%)
|
10. (95.3%)
|
NS
|
|
Bilateral
|
12 (5.5%)
|
7 (6.2%)
|
5 (4.7%)
|
NS
|
|
Histology
|
|
DCIS
|
24 (10.9%)
|
12 (10.6%)
|
12 (11.2%)
|
NS
|
|
IDC
|
181 (82.3%)
|
93 (82.3%)
|
88 (82.2%)
|
NS
|
|
ILC
|
13 (5.9%)
|
6 (5.3%)
|
7 (6.5%)
|
NS
|
|
Other
|
2 (0.9%)
|
2 (1.8%)
|
0 (0.0%)
|
NS
|
|
Grade
|
|
Grade 1
|
13 (5.9%)
|
7 (6.2%)
|
6 (5.6%)
|
NS
|
|
Grade 2
|
58 (26.4%)
|
35 (31.0%)
|
23 (21.5%)
|
NS
|
|
Grade 3
|
140 (63.6%)
|
68 (60.2%)
|
72 (67.3%)
|
NS
|
|
Unknown
|
9 (4.1%)
|
3 (2.7%)
|
6 (5.6%)
|
NS
|
|
Tumor Size
|
|
Mean size (mm)
|
27.02
|
30.80
|
22.95
|
<0.05
|
|
Median size (mm)
|
19.5
|
22.00
|
18.00
|
<0.05
|
|
ER status
|
|
Negative
|
104 (47.3%)
|
51 (45.1%)
|
53 (49.5%)
|
NS
|
|
Positive
|
113 (51.4%)
|
62 (54.9%)
|
51 (47.7%)
|
NS
|
|
Unknown
|
3 (1.4%)
|
0 (0.0%)
|
3 (2.8%)
|
NS
|
|
PR status
|
|
Negative
|
133 (60.5%)
|
67 (59.3%)
|
66 (61.7%)
|
NS
|
|
Positive
|
84 (38.2%)
|
46 (40.7%)
|
38 (35.5%)
|
NS
|
|
Unknown
|
3 (1.4%)
|
0 (0.0%)
|
3 (2.8%)
|
NS
|
|
HER-2 Status
|
|
Negative
|
158 (71.8%)
|
89 (78.8%)
|
69 (64.5%)
|
<0.05
|
|
Positive
|
14 (6.4%)
|
11 (9.7%)
|
3 (2.8%)
|
<0.05
|
|
Not performed or unknown
|
48 (21.8%)
|
13 (11.5%)
|
35 (32.7%)
|
<0.05
|
|
Triple negative breast cancer
|
|
Yes
|
80 (36.4%)
|
43 (38.1%)
|
37 (34.6%)
|
NS
|
|
No
|
92 (41.8%)
|
57 (50.4%)
|
35 (32.7%)
|
<0.05
|
|
Unknown
|
48 (21.8%)
|
13 (11.5%)
|
35 (32.7%)
|
<0.05
|
|
T- Stage
|
|
Tis
|
24 (10.9%)
|
12 (10.6%)
|
12 (11.2%)
|
NS
|
|
T1
|
101 (45.9%)
|
46 (40.7%)
|
55 (51.4%)
|
NS
|
|
T2
|
66 (30.0%)
|
38 (33.6%)
|
28 (26.2%)
|
NS
|
|
T3
|
23 (10.5%)
|
12 (10.6%)
|
11 (10.3%)
|
NS
|
|
T4
|
6 (2.7%)
|
5 (4.4%)
|
1 (0.9%)
|
NS
|
|
N-Stage
|
|
N0
|
133 (60.5%)
|
67 (59.3%)
|
66 (61.7%)
|
NS
|
|
N1
|
69 (31.4%)
|
32 (28.3%)
|
37 (34.6%)
|
NS
|
|
N2
|
15 (6.8%)
|
12 (10.6%)
|
3 (2.8%)
|
<0.05
|
|
N3
|
3 (1.4%)
|
2 (1.8%)
|
1 (0.9%)
|
NS
|
|
Overall TNM Stage
|
|
Stage 0 (In-situ)
|
24 (10.9%)
|
12 (10.6%)
|
12 (11.2%)
|
NS
|
|
Stage I
|
79 (35.9%)
|
37 (32.7%)
|
42 (39.3%)
|
NS
|
|
Stage II
|
83 (37.7%)
|
42 (37.2%)
|
41 (38.3%)
|
NS
|
|
Stage III
|
34 (15.5%)
|
22 (19.5%)
|
12 (112.2%)
|
NS
|
|
Adjuvant radiation
|
|
Yes
|
104 (47.3%)
|
42 (37.2%)
|
62 (57.9%)
|
<0.05
|
|
No
|
116 (52.7%)
|
71 (62.8%)
|
45 (42.1%)
|
<0.05
|
|
Chemotherapy
|
|
None
|
71 (32.3%)
|
31 (27.4%)
|
40 (37.4%)
|
NS
|
|
Neoadjuvant chemotherapy
|
49 (22.3%)
|
43 (38.1%)
|
6 (5.6%)
|
<0.05
|
|
Adjuvant chemotherapy
|
100 (45.4%)
|
39 (34.5%)
|
61 (57.0%)
|
<0.05
|
|
BRCA1/2 results
|
|
BRCA1 mutation
|
111 (50.5%)
|
56 (49.6%)
|
55 (51.4%)
|
NS
|
|
BRCA2 mutation
|
109 (49.5%)
|
57 (50.4%)
|
52 (48.6%)
|
NS
|
